---
title: "Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295172257.md"
description: "Individuals with inside information could potentially receive significant financial advantages that regular shareholders do not have access to. The suggested deals might include conditions that restrict better competing bids. Shareholders are advised to get in touch with the company to explore their entitlements and choices without incurring any charges."
datetime: "2026-08-07T02:33:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295172257.md)
  - [en](https://longbridge.com/en/news/295172257.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295172257.md)
generator: "portal-rs"
---

# Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders?

Individuals with inside information could potentially receive significant financial advantages that regular shareholders do not have access to. The suggested deals might include conditions that restrict better competing bids. Shareholders are advised to get in touch with the company to explore their entitlements and choices without incurring any charges.

### Related Stocks

- [VEEE.US](https://longbridge.com/en/quote/VEEE.US.md)
- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)
- [UTZ.US](https://longbridge.com/en/quote/UTZ.US.md)

## Related News & Research

- [Bank of New York Mellon Corp Invests $14.73 Million in Crinetics Pharmaceuticals, Inc. $CRNX](https://longbridge.com/en/news/297746024.md)
- [Crinetics Pharmaceuticals Completes Merger and Delists Shares](https://longbridge.com/en/news/297680237.md)
- [Faron Pharmaceuticals Ltd: Holding(s) In Company](https://longbridge.com/en/news/298025632.md)
- [Adarx Pharmaceuticals Announces Initial Public Offering Of Common Stock, SEC Filing](https://longbridge.com/en/news/298077949.md)
- [Heights Capital cuts Faron Pharmaceuticals voting rights to 20.25%](https://longbridge.com/en/news/298224452.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**